COVID-19-Related Inhibitors

Small molecule inhibitors that are able to block entry, replication, or subsequent host immune responses induced by SARS-CoV-2 (2019-nCoV) are of great interest in investigating therapeutic strategies to treat and prevent Coronavirus Disease-2019 (COVID-19). InvivoGen offers a selection of inhibitors known to act at different stages of the infection.

 

SARS-CoV-2 fusion inhibitor

Coronaviruses, such as SARS-CoV and SARS-CoV-2, have the capacity to use fusion with the surface membrane of target cells in order to deliver their viral RNA genome into the cytoplasm. In the case of COVID-19, targeting the fusion machinery of SARS-CoV-2 is a promising therapeutic strategy.

• EK1C4

Endosomal acidification inhibitors

Targets of COVID-19-Related inhibitors

Coronaviruses, such as SARS-CoV and presumably SARS-CoV-2, enter and are trafficked through the host cell in endosomes. Targeting and blocking endosomal acidification may help further study how SARS-CoV-2 infects host cells.

• Chloroquine
• Bafilomycin A1

JAK/STAT signaling inhibitor

 

Activation of the JAK/STAT pathway by type I IFNs amplifies their action through the production of a plethora of IFN-stimulated genes. However, in the case of COVID‑19, this can lead to hyper-inflammation and ultimately to a cytokine storm. Inhibiting this pathway will help further investigations into the COVID‑19 associated cytokine storm.

• Ruxolitinib

 

InvivoGen’s products are for research use only, and not for clinical or veterinary use.